null
Elotuzumab: Revolutionizing Multiple Myeloma Treatment and Research Applications

Elotuzumab: Revolutionizing Multiple Myeloma Treatment and Research Applications

Quick Facts About Elotuzumab

What is Elotuzumab?

Elotuzumab is a monoclonal antibody designed to enhance the immune system's ability to detect and destroy multiple myeloma cells. It targets the SLAMF7 protein, which is present on both myeloma and immune natural killer (NK) cells.

How does Elotuzumab work?

Elotuzumab activates NK cells by binding to SLAMF7, boosting their ability to attack cancer cells. It also directly marks myeloma cells for immune system destruction, making it a dual-action therapy.

What is Elotuzumab used for?

Primarily, Elotuzumab is used in combination therapies for relapsed or refractory multiple myeloma. These include pairings with drugs like lenalidomide, pomalidomide, and dexamethasone.

1.) Understanding Elotuzumab

Elotuzumab represents a significant advancement in immunotherapy, particularly for treating multiple myeloma. It selectively binds to SLAMF7, a protein highly expressed on myeloma cells and natural killer (NK) cells, enhancing immune-mediated destruction of cancer cells. Since its FDA approval, Elotuzumab has been a cornerstone in combination therapies for relapsed or refractory multiple myeloma.

2.) Mechanism of Action of Elotuzumab

Elotuzumab operates through dual mechanisms:


1.) Immune Activation: It binds to SLAMF7 on NK cells, enhancing their cytotoxic activity against myeloma cells.


2.) Direct Targeting: By attaching to SLAMF7 on myeloma cells, it flags them for destruction by the immune system.


This dual mechanism makes Elotuzumab a vital therapeutic option, particularly when used in combination with immunomodulatory drugs.

3.) Clinical Applications of Elotuzumab

Elotuzumab has proven efficacy in multiple myeloma treatment regimens. Common combinations include


  • Elotuzumab with Lenalidomide and Dexamethasone: Approved for newly diagnosed and relapsed cases.
  • Elotuzumab with Pomalidomide and Dexamethasone: Typically used for patients with relapsed or refractory multiple myeloma.

Ongoing research explores new combinations and its potential in other hematologic malignancies.

4.) Advancing Research on Elotuzumab with Biosimilars

What is a Biosimilar?

A biosimilar is a biologic product highly similar to an existing FDA-approved biologic, known as the reference product. Biosimilars offer comparable safety, purity, and potency while being more cost-effective, enhancing research accessibility.

Product Thumbnail
Elotuzumab (Anti-CS1) Biosimilar Antibody
Antibody Type:Monoclonal Antibody
Protein:CS1
Reactivity:Human
View Biosimilar

The Role of Elotuzumab Biosimilars in Research

Our Elotuzumab biosimilar provides researchers with a reliable tool for exploring:
  • SLAMF7 targeting mechanisms.
  • Combination therapies in preclinical settings.
  • Pathways involved in immune-mediated cancer cell destruction.

Benefits of Elotuzumab Biosimilars

  • Cost-Effective : Reduces research expenses compared to reference products.
  • High Quality: Maintains rigorous standards for research applications.
  • Research-Use Only: Ideal for experimental and preclinical studies, ensuring compliance with regulatory guidelines.

Discover Our Biosimilar Range

At Assay Genie, we specialize in providing high-quality biosimilars for research use! Check out our full biosimilar range to learn more.

Authors Thumbnail

Wrote by Shanza Riaz

Shanza Riaz is a dedicated biologist and academic researcher with a strong passion for the life sciences. Currently pursuing a PhD, Shanza specializes in genetics and computational biology. Her work includes research on genetic variations in the Kruppel-like factor protein family and their role in metabolic disease development.
26th Nov 2024 Shanza Riaz

Recent Posts